A5102758068- CAR-T cell therapy research
- Immunotherapy and Immune Responses
- Cancer Immunotherapy and Biomarkers
- Immune Cell Function and Interaction
- Cancer Research and Treatments
- RNA Interference and Gene Delivery
- Melanoma and MAPK Pathways
- SARS-CoV-2 and COVID-19 Research
- Chronic Lymphocytic Leukemia Research
- Hedgehog Signaling Pathway Studies
- Monoclonal and Polyclonal Antibodies Research
- Viral Infectious Diseases and Gene Expression in Insects
- Nonmelanoma Skin Cancer Studies
- Virus-based gene therapy research
- Cancer Cells and Metastasis
- Tumors and Oncological Cases
Technical University of Denmark
2024
Copenhagen University Hospital
2015-2024
Gentofte Hospital
2010-2021
University of Copenhagen
2018-2020
Herlev Hospital
2015-2018
Capital Region of Denmark
2010
Objective:Ovarian cancer (OC) is often diagnosed at an advanced stage with two thirds of patients experiencing recurrent disease a poor prognosis. Adoptive cell therapy (ACT) tumor-infiltrating lymphocytes (TIL) has shown curative potential in malignant melanoma, but only been investigated scarcely other cancers. In this pilot study, we tested TIL based ACT metastatic OC.Methods:Six progressive platinum-resistant OC were treated infusion preceded by standard lymphodepleting chemotherapy and...
Background Adoptive cell therapy (ACT) with tumor-infiltrating lymphocytes (TILs) has shown remarkable results in malignant melanoma (MM), while studies on the potential other cancer diagnoses are sparse. Further, prospect of using checkpoint inhibitors (CPIs) to support TIL production and remains be explored. Study design TIL-based ACT CPIs was evaluated a clinical phase I/II trial. Ipilimumab (3 mg/kg) administered prior tumor resection nivolumab mg/kg, every 2 weeks ×4) relation infusion....
e22070 Background: Basal cell carcinoma (BCC) is the most frequent malignancy. Case reports have described effect of immune checkpoint blocking antibodies (ICB) against PD-1 in BCC (Cannon et al. 2018, Chang 2017, Ikeda 2016, Winkler 2017). Autoimmune side effects ICB are well known and limits a wider use BCC. IO103 peptide vaccine major programmed death (PD) ligand 1 (PD-L1). In first-in-man study patients with multiple myeloma (NCT03042793) regression co-existing was observed two which...
<h3>Background</h3> Adoptive cell therapy (ACT) with tumour-infiltrating lymphocytes (TILs) entails the isolation, expansion, and reinfusion of autologous TILs to enhance immune system's ability recognize eradicate tumour cells. Mutations in cells may lead generation neoantigens which display various degrees homology common microbial antigens. We therefore decided investigate whether efficacy cancer immunotherapy, observed some patients, might be contributable boosting an existing...
Meeting abstracts The human Vγ9Vδ2 T cells are a unique cell type, and recent studies of the biology emphasize potential exploitation these in immunotherapy cancer. exhibit dual functionality that they both antigen presenting (